We report an evaluation of the GammafloTM automated continuous-flow radioimmunoassay instrument in which we used a digoxin assay to assess system performance. System operation was based on combined continuous-flow and column-chromatographic techniques. No drift or carryover was detectable in 180 within-assay consecutive determinations performed at a rate of 42 determinations per hour (5 h of continuous operation). Within-assay and between-assay precision were less than 6% (coefficient of variation). The automated method correlated well (r = 0.960 and 0.952, respectively) with two established manual digoxin radioimmunoassay procedures. The data suggest this automated system offers a valid alternative to manual radioimmunoassay procedures in terms of overall precision, simplicity of operation, and sample throughput capacity. vention, and the availability of RIA results in minutes rather than hours. They also concluded that one important aspect of the system would be its ability to offer laboratories the flexibility of doing a series of different radioimmunoassays faster than would be possible by other tedious manual methods.
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We report an evaluation of the GammafloTM automated continuous-flow radioimmunoassay instrument in which we used a digoxin assay to assess system performance. System operation was based on combined continuous-flow and column-chromatographic techniques. No drift or carryover was detectable in 180 within-assay consecutive determinations performed at a rate of 42 determinations per hour (5 h of continuous operation). Within-assay and between-assay precision were less than 6% (coefficient of variation). The automated method correlated well (r = 0.960 and 0.952, respectively) with two established manual digoxin radioimmunoassay procedures. The data suggest this automated system offers a valid alternative to manual radioimmunoassay procedures in terms of overall precision, simplicity of operation, and sample throughput capacity. (1). These manual procedures are often a source of human error and emphasize the need for RIA automation. To date, a number of methods have been proposed for the automation of RIA procedures (2) (3) (4) . A major problem in automating these procedures has been the separation of the bound from the free radiolabeled fractions and the coupling of that step to the counting of radioactivity. In 1976 Brooker, Terasaki, and Price (5) introduced the "Gammaflow"
system. This system combined continuous-flow methodology with column chromatography techniques for separation of bound from free radiolabeled ligand. Interruption of flow (continuous flow/stopped flow) was used to allow for counting of the radioactive fraction. The system combined the sample or standards with the labeled ligand and antibody, incubated the mixture, then separated and determined the amount of bound ligand. The amount of unknown in the sample was then calculated by the instrument by comparison with a standard curve. The entire sequence of operation was computer controlled. In the original publication describing Gammaflow (5), the authors mentioned several potential advantages to this system, including simplicity of change-over from one assay to another, flexibility in types of assay the system could accommodate, flexibility in the number of samples assayed per hour, the capability of operation without technologist inter- vention, and the availability of RIA results in minutes rather than hours. They also concluded that one important aspect of the system would be its ability to offer laboratories the flexibility of doing a series of different radioimmunoassays faster than would be possible by other tedious manual methods.
We have evaluated the performance characteristics of a pre-production model of the Gammaflo Automated Assay
System (E.R. Squibb & Sons, Inc., Princeton, NJ 08540) with particular reference to sources of analytical error commonly encountered in continuous-flow and radioimmunoassay methodologies. An assay for serum digoxin was used as a model assay for this evaluation.
Materials and Methods

Apparatus
The pre-production model of the Gammaflo Automated Assay System consisted of a peristaltic pump, a sample and reagent pickup device, a sodium iodide/photomultiplier gamma-radiation detector, a replaceable column to separate free from bound radioactivity, a series of solenoid valves to control solution flow, and a microcomputer for data reduction and system control. These subsystems were integrated in a self-contained instrument and the counting portions of the system. Free radioligand was separated from bound on a replaceable anion-exchange resin separating column. The radioactive fraction (bound fraction) was counted by a stopped-flow technique that allowed for stationary counting of this bound fraction and the fraction's subsequent rapid elimination from the detection system.
The instrument is computer controlled and has available several modes for data reduction. The curve-fitting routines available on the system are logit-log, weighted logit-log, and third-order polynomial. In this study we used the third-order polynomial regression for all determinations. This routine fitted the number of bound counts against the square root of the analyte concentration (dose). A standard curve is printed followed by a printout of the sample and control values in B (bound counts), B/Bo ratio (B0 represents total bound count for a zero-concentration standard), and preselected concen- 
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***..e.**#{149}*a**.***.*e.#{149}.*#{149}#{149}.#{149}**e#{149}*#{149}*#{149}************e**e*e****e*e**eee***e.**.******ee.*..**** for the present studies, except where indicated). A hard-copy printout obtained for a typical digoxin standard curve is shown in Figure 1 . Besides the standard curve, the printout also provided the number of bound counts, the B/B0 ratio, the declared standard concentrations, the calculated concentrations based on the curve with best fit to data, and the percentage difference between these two concentrations. During the evaluation, we made more than 1800 determinations in separate assays. The number of replicate determinations per sample cup varied depending on the nature of the experiment. We used two manual assays in the correlation studies. With the Digoxin Immutopet Kit (E.R. Squibb), all samples were analyzed in duplicate, and the radioactivity was counted with a Gamma 4000 system (Beckman Instruments, Inc., Fullerton, CA 92634). The second manual assay, with the Schwarz/Mann Radioimmunoassay Kit (cat. no. 200816; Becton-Dickinsoii Immunodiagnostics, Orangeburg, NY 10962), was performed at the North Carolina Memorial Hospital, Chapel Hill, NC. Both of these manual procedures involved liquid-phase systems in which powdered charcoal was used to separate the bound from the free radioactive fractions. The standards used were as supplied with each kit. We used the Gammaflo computer in the manual entry and computation mode for data reduction of the data obtained with the Immutope manual assay.
Results
System Stability
The results of two separate experiments for evaluating system drift and carryover are summarized in Figure 2 . The first of these experiments (solid symbols) represents the results of 165 digoxin determinations in which controls were at' concentrations of 0,0.50, 2.00, and 4.00 g/L. The assays were consecutive and each set of 15 values at the given concentrations was taken from a separate sample cup. There was no detectable drift over a period of 4 h of continuous system operation, as defined by there being no significant differences (p = 0.057) among the mean values for each cluster of 15 determinations for any given concentration over the time range studied. In addition, we detected no carryover (6) between the different concentrations; i.e., the mean of the first duplicate 
Reagents
All reagents, standards, and controls for the Gammaflo were supplied by E.R. Squibb. Digoxin antiserum was rabbit antidigoxin. The '25I-labeled digoxigenin concentrate, supplied in 1.5-mL quantities with a total radioactivity of less than 45 was stored at -20 #{176}C. The digoxigenin diluent was an albumin-based protein matrix. The working radiolabeled antigen was prepared by diluting the '25I-labeled digoxigenin concentrate with digoxigenin diluent to register 72 000 ± 2000 cpm per 50 tL (a typical dilution of concentrate to diluent was 1:15). Diluted radiolabeled antigen was stored at 4 #{176}C and used within one week. Digoxin standards were 0.25,0.75, 1.50, 3.00, and 5.00 /2g/L, and controls were 0.50, 2.00, and 4.00 g/L, both supplied in an albumin-protein matrix. The digoxin working buffer was prepared by dilution of 100 mL of a concentrated acetate/phosphate buffer to a final volume of 1 L with de-ionized H20 and then stored at room temperature. This buffer concentrate (potassium phosphate, 0.25 mol/L; and acetic acid containing 0.25 mol of sodium acetate and 1 g of sodium azide per liter) had a pH of 4.8 and contained Brij 35 surfactant (1.5 g/L). A column-wash solution was supplied by the manufacturer. The anion-exchange resin was BioRad AG 1 X 4, also supplied by the manufacturer.
Unless otherwise stated, all reagents and standards were stored at 4 #{176}C and equilibrated to room temperature before use.
Procedures
All automated digoxin assays were performed under the conditions and parameters detailed in Table 1 . A fresh column (2 mL bed volume) was used for each assay run. Analysis was initiated by keyboard entry of the assay type (digoxin) and the number of sample replicate determinations desired (two 
In a second study (Figure 2 , open symbols) we made replicate analyses of a control sample with a digoxin concentration of 2.00 zg/L for more than Table 2 .
Inter-assay precision was determined by analyzing the three control samples over 15 days, with two separate determinations each day (Table 2) . Fresh buffers and radioligand were prepared for every fifth set of determinations. To simulate routine laboratory performance, we assayed cups containing serum samples from patients between all control cup positions. New bottles of controls were used for every assay, to check vial-to-vial variability.
Instrument within-assay counting precision
for the number of bound counts from a zero standard was 5034 ± 108 counts per 32s (CV = 2.8%, n = 30). The observed blank count (counts of radioactive analyte passing through the separation column in the absence of antibody), which included instrument and reagent background and nonspecific binding, was typically less than 10% of the measured zero-standard counts.
Within-assay reproducibility of the sample/reagent incubation time, defined as the time interval between sample pick-up and valve sequence trigger, was 381.4 ± 0.54 s (CV = 0.14%, n = 50). This incubation time, in minutes and seconds, was printed out for each assay determination as a diagnostic quality-control parameter. We examined the dependence of the assay on specimen cup fill-level by introducing a fourfold change in sample cup filllevel at each of three control concentrations. Results for the three concentrations before and after changes in cup level were: 4.01 ± 0.11 vs. 3.97 ± 0.09; 2.04 ± 0.14 vs. 2.05 ± 0.06; and 0.46 ± 0.04 vs. 0.40 ± 0.08 g/L, with n = 4 determinations in each measurement.
Accuracy
Accuracy was assessed by recovery, parallelism, and correlation studies with patients' samples. The recovery of the digoxin assay was determined by the recovery of gravimetrically measured amounts of digoxin that had been predissolved in ethanol (600 mL/L) and then quantitatively added to a serum pool containing 0.26 mg of digoxin per liter. Enough digoxin was added to this pool to yield concentrations of 1.26, 2.26, and 4.26 xg/L; five samples were prepared at each concentration and were assayed in duplicate. The recoveries of added digoxin were 98, 95, and 93% for these three concentrations, respectively, with a mean of 96%. The quantitative recovery of digoxin added to serum suggested that the serum matrix had neither an inhibitory nor augmentative effect on the measured digoxin. This conclusion was confirmed by comparison of immunochemical identity (parallelism) of serum digoxin with standard and control materials, as determined by preparing a series of dilutions, measuring the concentrations on the Gammaflo, and then correlating results to the known serum dilutions (7, 8) . 
Discussion
Our study is the first reported field evaluation of this automated system. We chose to evaluate this instrument in terms of assessing parameters and possible sources of errors of importance for system operation in a routine clinical laboratory setting. The instrument was evaluated with a digoxin assay, which is a commonly used RIA procedure and one that frequently requires a high sample throughput.
The reproducibility and stability of this system over the periods of time studied appeared to be excellent. Relative intraand inter-assay standard deviations and the system stability observed for the digoxin assay were comparable to 
